KRAS and colorectal cancer: Supporting this hypothesis, in the above mentioned ASPECCT trial, a randomised phase 3 trial that compared Pmab and Cmab in patients with chemotherapy-refractory WT KRAS exon 2 colorectal cancer, the incidence of grade 3–4 hypomagnesaemia was significantly higher in patients treated with Pmab than in patients treated with Cmab (7% vs 3%) [20].